

2025 2Q Earnings Release

Beyond the Limits Discover, Connect, Create



Disclaimer

The financial information contained herein has been prepared in accordance with K-IFRS.

This presentation includes forward-looking statements that reflect the current business environment and the Company's management strategies. Please be advised that actual results may differ materially due to changes in future business conditions or adjustments in strategy.

This material is not intended to serve as legal evidence for any liability related to investment decisions.

SK chemicals

Revenue: KRW 596.9bn (YoY +44.2%)
Operating Loss: KRW 1.0bn
(YoY turned to deficit)

- Green Chemicals Biz., exclusive partnership agreement w/ Durmont



- SKBS, completion of G2+ facility

SK gas

Revenue: KRW 1,880.3bn
(YoY +13.9%)
Operating Profit: KRW 120.7bn
(YoY +157.0%)

- Commercial operation of Ulsan Hydrogen Fuel Cell Power Plant commenced (June 2025)



- Value-up Index 100 (June 13)

SK plasma


Revenue: KRW 49.8bn (YoY +10.5%)
Operating Loss: KRW 2.3bn
(YoY turned to deficit)

- Tech transfer figures excluded
* 9 straight quarters of OP (separate)
- Co-development & license agreement w/ AIMEDBIO




Consolidated Basis

(Unit : KRW bn)	2Q24	1Q25	2Q25	YoY	QoQ
Revenue	2,119.4	2,406.1	2,497.8	+17.9%	+3.8%
Operating Profit	39.6	110.7	88.0	+122.5%	△20.5%
Profit before Tax	36.8	89.3	7.3	△80.1%	△91.8%
Net Profit	16.3	73.5	22.0	+35.3%	△70.0%



Financial Results (Consolidated)



Financial Highlights

◆ Green Chemicals – Copoly & Monomer

- **Profit growth** driven by expanded sales of high-value-added products
 - 2Q25 OP: KRW 40.0bn (YoY +8.3%)
- Outlook
 - Portfolio expansion vs. Geopolitical risks

◆ Life Science – Pharma


- **Strong sales of key products** and distribution
 - 2Q25 OP: KRW 8.2bn (YoY 117.3%)
- Outlook
 - Strengthening marketing for key products vs. Increase in marketing costs

◆ Life Science – SKBS

- Top-line growth attributed to increased sales of basic vaccines and **consolidation effects of IDT**
 - 2Q25 IDT revenue: KRW 129.3n
- Outlook
 - SKYVAX sales ramp up
 - + Expansion of Sanofi vaccine distribution

Financial Results (Consolidated)

■ Revenue ○— Operating Profit (Unit : KRW bn)



Financial Highlights

◆ LPG Biz.


- Strong performance through optimized market response
 - **Expanded trading** leveraging market volatility
 - Generated additional profit through LNG/LPG paper optionality trading
- Outlook
 - Continue cost reduction through O/I

◆ Power Biz. (Ulsan GPS)

- **Decreased power generation profit** QoQ due to planned maintenance
 - Bid/generation decreased by approx. 60% QoQ
- Outlook
 - Expected profit increase in the 2H, based on stable operations and **seasonal peak demand**
 - **Anticipated rise in SMP*** due to increased electricity demand from summer heatwaves

* SMP : System Marginal Price

Financial Results (Consolidated)



Financial Highlights

◆ Indonesia JV – tech transfer figures excluded

- (separate) **Revenue KRW 55.8bn, OP KRW 4.7bn**
* **9 straight quarters of OP** since 1H23
- Tech transfer fee first recognized in 4Q24, further recognition planned quarterly in 2025

◆ Outlook: IPO planned post-2026


- KRW 153bn additional investment secured in '24.
- Ongoing efforts to improve financials

◆ Order backlog (as of 2Q25)

(Unit : KRW bn)


Country	Order Date	Delivery Date	Total Order Amount	Order Backlog
3 Middle East Countries	2022.01.05	~2026.12.31	39.4	9.4
8 South American Countries	2022.01.26	~2029.01.25	38.4	37.7
Ecuador	2022.02.22	~2026.02.22	9.0	9.0
Singapore	2022.01.18	~2025.12.31	13.6	-
Indonesia	2024.12.09	~2026.12.08	82.0	82.0
Total			182.3	138.0

Ownership Structure



Shareholder Composition


Category	No. of Shares
Largest Shareholder(s)	9,358,047
Treasury Shares	1,170,137
Foreign Investors	2,335,913
Institutions	621,117
Individuals & Others	4,862,641
Total Shares Issued	18,347,855



※ Based on common shares as of the end of 1Q25

- 1) Interim dividends implemented since 2022.
- 2) Share repurchase and cancellation program in progress (2023-2025, KRW 60bn)
- 3) From the 2024 interim dividend, dividend procedure revised to enhance predictability:
“Dividend amount confirmed first → Record date designated later”

Dividend Receipts and Distributions



Share Repurchase and Cancellation

- | | |
|------------------|---|
| Policy | <ul style="list-style-type: none"> ▪ Share repurchase and cancellation planned over 2023-2025 (KRW 60bn) - Aimed at enhancing shareholder value by increasing shareholder return ratio |
| Execution | <ul style="list-style-type: none"> ▪ 2023: repurchase and cancellation completed (KRW 10bn) ▪ 2024: repurchase and cancellation completed (KRW 20bn) ▪ 2025: repurchase in progress (KRW 30bn) |

Future Plan

- ◆ All treasury shares repurchased in 2025 to be fully cancelled
 - Subject to board approval; cancellation timing to be reviewed and confirmed
- ◆ Mid-term dividend policy to be reviewed
 - The review will consider the Company's financial position, investment plans, and overall business environment

Consolidated Basis

(Unit : KRW bn)	1Q25	2Q25	QoQ
Total Assets	15,549	15,442	△107
Current Assets	6,022	5,558	△463
Non-current Assets	9,528	9,884	+356
Total Liabilities	9,052	8,933	△119
Current Liabilities	3,956	3,862	△93
Non-current Liabilities	5,097	5,070	△26
Total Equity	6,497	6,510	+12
Debt Ratio	139.3%	137.2%	△2.1%p

Separate Basis

(Unit : KRW bn)	1Q25	2Q25	QoQ
Total Assets	1,964	1,790	△174
Current Assets	460	120	△340
Non-current Assets	1,504	1,670	+166
Total Liabilities	931	802	△128
Current Liabilities	573	460	△113
Non-current Liabilities	358	343	△15
Total Equity	1,033	988	△46
Debt Ratio	90.1%	81.3%	△8.8%p